NPI: 1417913419 · MOUNTAIN VIEW, AR 72560 · Critical Access Hospital · NPI assigned 04/26/2006
Authorized official BAXTER, SHAWNA controls 20+ related entities in our dataset. Read more
| Authorized Official | BAXTER, SHAWNA (PROVIDER ENROLLMENT) |
| NPI Enumeration Date | 04/26/2006 |
Other providers sharing the same authorized official: BAXTER, SHAWNA
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 20,393 | $457K |
| 2019 | 26,731 | $619K |
| 2020 | 27,245 | $471K |
| 2021 | 25,055 | $527K |
| 2022 | 23,433 | $487K |
| 2023 | 22,677 | $432K |
| 2024 | 16,235 | $307K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 2,715 | 1,569 | $399K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2,566 | 1,534 | $313K |
| 80053 | Comprehensive metabolic panel | 11,834 | 9,374 | $249K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3,747 | 2,673 | $244K |
| 87631 | 1,444 | 1,386 | $166K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1,861 | 1,566 | $159K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3,364 | 916 | $133K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1,414 | 1,231 | $125K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 721 | 655 | $104K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2,176 | 2,001 | $99K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3,145 | 2,199 | $96K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1,248 | 1,087 | $90K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 12,844 | 9,037 | $71K |
| 36415 | Collection of venous blood by venipuncture | 16,761 | 11,626 | $57K |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 3,626 | 2,536 | $57K |
| 80048 | Basic metabolic panel (calcium, ionized) | 4,141 | 2,930 | $53K |
| 71046 | Radiologic examination, chest; 2 views | 3,256 | 2,793 | $51K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1,319 | 1,197 | $50K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2,819 | 2,112 | $48K |
| 83880 | 2,536 | 2,053 | $38K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4,592 | 3,595 | $38K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 373 | 257 | $30K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1,061 | 946 | $30K |
| 84443 | Thyroid stimulating hormone (TSH) | 2,371 | 2,166 | $29K |
| 84484 | 4,371 | 2,663 | $26K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 387 | 369 | $24K |
| 99284 | Emergency department visit for the evaluation and management, high severity | 2,632 | 1,865 | $23K |
| 81001 | 6,708 | 5,577 | $22K | |
| 87040 | 1,815 | 1,174 | $22K | |
| 85027 | 3,332 | 2,832 | $19K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2,291 | 1,958 | $18K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 736 | 605 | $18K |
| 82553 | 2,246 | 1,495 | $17K | |
| 71045 | Radiologic examination, chest; single view | 2,383 | 1,998 | $17K |
| 82550 | 2,673 | 1,673 | $17K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1,365 | 839 | $16K |
| 64493 | 71 | 58 | $16K | |
| 87077 | 1,428 | 1,209 | $16K | |
| 64635 | 51 | 43 | $14K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 94 | 76 | $14K |
| 62323 | 103 | 75 | $13K | |
| 81025 | 1,448 | 1,268 | $13K | |
| 96376 | 596 | 327 | $12K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 402 | 358 | $11K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,426 | 1,294 | $11K |
| 82150 | 1,396 | 1,211 | $11K | |
| 83690 | 1,302 | 1,102 | $10K | |
| 83735 | 2,008 | 1,640 | $10K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 2,426 | 1,733 | $10K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 2,051 | 1,505 | $9K |
| 80061 | Lipid panel | 908 | 834 | $9K |
| 82962 | 2,430 | 797 | $9K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 187 | 167 | $8K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 283 | 265 | $8K |
| T1015 | Clinic visit/encounter, all-inclusive | 720 | 566 | $7K |
| 84145 | 812 | 588 | $7K | |
| 87186 | 1,332 | 1,145 | $7K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 30 | 26 | $6K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 745 | 466 | $6K |
| 87632 | 35 | 35 | $5K | |
| 80305 | 537 | 458 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 3,155 | 2,150 | $5K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 90 | 54 | $4K |
| 85610 | 1,517 | 1,111 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 589 | 507 | $4K |
| 83605 | 724 | 487 | $4K | |
| 85378 | 656 | 543 | $4K | |
| 82607 | 359 | 342 | $4K | |
| G0378 | Hospital observation service, per hour | 1,426 | 742 | $4K |
| 73630 | 128 | 109 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 97 | 72 | $4K |
| 71020 | 263 | 227 | $3K | |
| 97162 | 41 | 37 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 14 | 12 | $3K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 17 | 14 | $3K |
| 87070 | 235 | 202 | $3K | |
| 73562 | 68 | 52 | $2K | |
| 87807 | 213 | 186 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 330 | 305 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 12 | 12 | $2K |
| 87428 | 31 | 31 | $2K | |
| 87581 | 35 | 35 | $2K | |
| 87486 | 35 | 35 | $2K | |
| 87400 | 377 | 302 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 12 | 12 | $1K |
| 64494 | 57 | 46 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 45 | 28 | $1K |
| 87503 | 35 | 35 | $935.04 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 111 | 108 | $929.94 |
| 86757 | 51 | 30 | $927.04 | |
| 73030 | 51 | 36 | $854.41 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 982 | 768 | $774.99 |
| 86666 | 43 | 30 | $713.14 | |
| 73130 | 13 | 12 | $560.93 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 843 | 608 | $515.87 |
| 86617 | 37 | 30 | $498.36 | |
| 72110 | 12 | 12 | $495.80 | |
| 80050 | General health panel | 14 | 13 | $438.03 |
| 94760 | 33 | 26 | $343.56 | |
| 86668 | 37 | 30 | $334.94 | |
| J2704 | Injection, propofol, 10 mg | 791 | 538 | $322.81 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 23 | 12 | $317.80 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 1,328 | 772 | $312.03 |
| 74022 | 15 | 13 | $296.64 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 188 | 52 | $245.20 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 169 | 160 | $230.48 |
| 73610 | 14 | 12 | $218.00 | |
| 85652 | 29 | 26 | $212.90 | |
| 51702 | 24 | 12 | $196.00 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 23 | 12 | $181.17 |
| 82803 | 16 | 13 | $179.55 | |
| 64636 | 63 | 42 | $138.77 | |
| J3490 | Unclassified drugs | 30 | 13 | $110.85 |
| 86308 | 14 | 14 | $103.46 | |
| 85730 | 12 | 12 | $62.38 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 101 | 64 | $61.31 |
| J0690 | Injection, cefazolin sodium, 500 mg | 109 | 50 | $41.32 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 97 | 76 | $30.25 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 39 | 27 | $24.34 |
| T1502 | Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit | 118 | 106 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 69 | 39 | $0.00 |
| 36600 | 15 | 12 | $0.00 |